GSK's depemokimab gets EMA nod for asthma and nasal polyps
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently undervalued according to InvestingPro Fair Value metrics, has reached a ...
Pharmabiz23d
EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP
GSK plc announced that the European Medicines ... multi-centre phase III clinical trials. The trials assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 adult and ...
GSK Reported Strong Earnings, So I Reiterate My Strong Buy
GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I reiterate strong buy rating on GSK stock.
Yahoo Finance23d
GSK announces EMA accepted for review the MAA for depemokimab
https://www.tipranks.com/news/the-fly/cigna-price-target-lowered-to-350-from-400-at-cantor-fitzgerald GSK (GSK) announced that the European Medicines Agency, EMA, has ...
Yahoo Finance23d
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation ...
Severe Asthma FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight
The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier ...